ICCC
IMMUCELL CORP /DE/Company Information
- Company Name
- IMMUCELL CORP /DE/
- CIK
- CIK0000811641
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ICCC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- ICCC
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-18
- Last sale
- —
- Shares purchased (TTM)
- 15,773
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,333,079
- Shares outstanding
- 9,064,785
- Ownership
- 14.71%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -9.17%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 7 | 4 | 4 | 6 | 5 | 4 | 4 | 1 | 1 | 1 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Accounts Receivable Net Current | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 2 | 2 | 3 | 2 | 2 | ||||||
| Inventory Net | 9 | 9 | 9 | 10 | 8 | 7 | 7 | 7 | 7 | 7 | 8 | 7 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | ||||||
| Assets Current | 21 | 19 | 17 | 17 | 17 | 16 | 15 | 14 | 11 | 11 | 11 | 12 | ||||||
| Property Plant And Equipment Net | 21 | 21 | 21 | 24 | 25 | 25 | 25 | 26 | 26 | 27 | 28 | 28 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | ||||||
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Finite Lived Intangible Assets Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 47 | 44 | 43 | 46 | 43 | 46 | 45 | 44 | 42 | 43 | 44 | 45 | ||||||
| Long Term Debt Current | 2 | 2 | 2 | 2 | 2 | - | 1 | - | - | - | - | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Long Term Debt And Capital Lease Obligations Current | - | - | - | - | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | ||||||
| Liabilities Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | ||||||
| Long Term Debt Noncurrent | 7 | 7 | 7 | 8 | 8 | - | 9 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Noncurrent | 11 | 11 | 11 | 12 | 12 | 13 | 13 | 14 | 14 | 14 | 15 | 15 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Debt And Capital Lease Obligations | - | - | - | - | - | 9 | 9 | 9 | 10 | 10 | 11 | 11 | ||||||
| Liabilities | 15 | 15 | 15 | 16 | 17 | 17 | 18 | 18 | 18 | 18 | 19 | 19 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 42 | 42 | 41 | 41 | 41 | 41 | 41 | 40 | 37 | 36 | 36 | 36 | ||||||
| Retained Earnings Accumulated Deficit | -11 | -13 | -15 | -12 | -12 | -13 | -14 | -15 | -14 | -12 | -12 | -11 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 31 | 29 | 27 | 30 | 30 | 29 | 28 | 26 | 23 | 25 | 25 | 26 | ||||||
| Liabilities And Stockholders Equity | 47 | 44 | 43 | 46 | 47 | 46 | 45 | 44 | 42 | 43 | 44 | 45 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | ||||||
| Common Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Common Stock Shares Issued | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIMMUCELL CORP /DE/ (ICCC) — SEC Financial Statements & Analysis
IMMUCELL CORP /DE/ (ICCC) is a in vitro & in vivo diagnostic substances company, incorporated in DE. IMMUCELL CORP /DE/ trades on Nasdaq as: ICCC. IMMUCELL CORP /DE/ (ICCC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, IMMUCELL CORP /DE/ carries a market cap of $91.10M, a P/E ratio of 115.70x, a P/B ratio of 2.90x, a P/S ratio of 2.97x, an enterprise value of $90.54M, and an EV/EBITDA multiple of 14.51x. On profitability, it posts a gross margin of 40.32%, an operating margin of 12.60%, a net margin of 2.57%, a Return on Equity (ROE) of 2.57%, a Return on Assets (ROA) of 1.77%, and a Return on Invested Capital (ROIC) of 11.01%. Per share, it reports EPS of $0.09, diluted EPS of $0.09, free cash flow per share of $0.46, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 8.49% year-over-year, net income growth of -55.31% year-over-year, and EPS growth of -55.47% year-over-year. On the balance sheet, it maintains a current ratio of 4.75x, a quick ratio of 2.65x, working capital of $16.64M, a debt-to-equity ratio of 0.49x, a debt ratio of 0.33, free cash flow of $4.21M (TTM), and net debt of $-557.32K. Figures sourced from SEC EDGAR.
- Market Cap
- $91.10M
- P/E TTM
- 115.70x
- EPS TTM
- $0.09
- P/B TTM
- 2.90x
- ROE TTM
- 2.57%
- ROA TTM
- 1.77%
- Debt To Equity
- 0.49x
- Free Cash Flow TTM
- $4.21M
- Net Revenue TTM Growth 1Y
- 8.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IMMUCELL CORP /DE/ in?
IMMUCELL CORP /DE/ (ICCC) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does ICCC trade on?
IMMUCELL CORP /DE/ (ICCC) trades on the Nasdaq.
Where is IMMUCELL CORP /DE/ incorporated?
IMMUCELL CORP /DE/ is incorporated in DE.
When was IMMUCELL CORP /DE/ (ICCC)'s most recent SEC filing?
IMMUCELL CORP /DE/ (ICCC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ICCC's market cap?
IMMUCELL CORP /DE/ (ICCC) has a market capitalization of $91.10M as of 2026-06-30.
What is ICCC's P/E ratio?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month P/E ratio is 115.70x as of 2026-06-30.
What is ICCC's EPS (earnings per share)?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month EPS is $0.09 as of 2026-06-30.
What is ICCC's ROE (return on equity)?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month Return on Equity (ROE) is 2.57% as of 2026-06-30.
What is ICCC's ROA (return on assets)?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month Return on Assets (ROA) is 1.77% as of 2026-06-30.
What is ICCC's ROIC (return on invested capital)?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month Return on Invested Capital (ROIC) is 11.01% as of 2026-06-30.
What is ICCC's EV/EBITDA?
IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month EV/EBITDA is 14.51x as of 2026-06-30.